Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today ...

From a virus's point of view, invading our cells is a matter of survival. The virus makes a living by highjacking cellular processes to produce more of the proteins that make it up. From our point of ...

U.K. scientists have used mass spectrometry to look in detail at how adeno-associated viruses (AAVs) release their genetic cargo when infecting host cells. The team, from the University of Leeds, ...

"If we can make a vaccine that is multivalent, we can protect against many strains of the virus," DuBois said. More ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

Gilead Sciences wins 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo: Foster City, California Monday, November 3, 2025, 17:00 Hrs [IST] Gilead Sciences, Inc ...

The USAN, consisting of members from the Food and Drug Administration (FDA), American Medical Association (AMA), United States Pharmacopeia (USP) and the American Pharmacists Association (APhA), is ...

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic ...